These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1902 related articles for article (PubMed ID: 34888843)

  • 1. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
    Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BTLA-HVEM complex - The future of cancer immunotherapy.
    Wojciechowicz K; Spodzieja M; Wardowska A
    Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
    Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
    Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
    Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Granda-Díaz R; Martínez-Pérez A; Aguilar-García C; Rodrigo JP; García-Pedrero JM; Gonzalez S
    Mol Cancer; 2023 Aug; 22(1):142. PubMed ID: 37649037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 13. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 15. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for anaplastic thyroid carcinoma: the present and future.
    Lu X; Bao L; Pan Z; Ge M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
    Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
    Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTLA inhibition has a dominant role in the
    Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
    Front Immunol; 2022; 13():956694. PubMed ID: 36081508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
    Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.